U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18ClN3O5S
Molecular Weight 435.881
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Rivaroxaban

SMILES

ClC1=CC=C(S1)C(=O)NC[C@H]2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O

InChI

InChIKey=KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1

HIDE SMILES / InChI
Molecular Formula C19H18ClN3O5S
Molecular Weight 435.881
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.biospace.com/News/bayer-healthcares-xarelto-rivaroxaban-becomes/244131

Rivaroxaban (trade name Xarelto) is an oral anticoagulant. It is the first available orally active direct factor Xa inhibitor. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prophylaxis of deep vein thrombosis (DVT) which may lead to PE in patients undergoing knee or hip replacement surgery, pulmonary embolism (PE) and for the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: Rivaroxaban is distributed heterogeneously to tissues and organs, exhibiting only moderate tissue affinity and does not substantially penetrate the blood-brain barrier.

Originator

Bayer
150
Curator's Comment: Rivaroxaban was discovered in Bayer HealthCare Pharmaceuticals' Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical. # Bayer HealthCare Pharmaceuticals

Approval Year

2011
587
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 0.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8583
XARELTO

Approved Use

Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
138.4 μg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.114 μg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.77 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
20 mg 1 times / day unknown, oral
dose: 20 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
20 mg 1 times / day unknown, oral
dose: 20 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg single, oral
Highest studied dose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
healthy, 19-45
Health Status: healthy
Age Group: 19-45
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
50 mg single, oral
Studied dose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
healthy, 60-76
Health Status: healthy
Age Group: 60-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 3-5, 4.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Disc. AE: Spinal epidural hematoma...
AEs leading to
discontinuation/dose reduction:
Spinal epidural hematoma
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (1.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Bleeding grade 3-5, 4.3%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Bleeding 2%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Spinal epidural hematoma Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Bleeding 1.7%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252

inducer
1087
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C8
1057

CYP2C19
2057

CYP2J2
33

P-gp
1741

BCRP
910
CYP3A4/5
91

CYP2J2
71

P-gp
2052

BCRP
697
CYP1A2
832

CYP2B6
669

CYP2C19
329
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
985
 no
CYP1A2
2333
 no
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2C19
2141
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP2J2
36
 no
CYP3A4
2633
 no
CYP3A4
2633
 no
P-gp
1932
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
697
 yes
CYP2J2
71
 yes
CYP3A4/5
91
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of rivaroxaban 0.7x, auc 1.6x
Page: 9.0
P-gp
2052
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of rivaroxaban 0.7x, auc 1.6x
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:68579
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68579
ChemicalBook
CB91176772
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91176772
eMolecules
27523812
https://www.emolecules.com/cgi-bin/more?vid=27523812
MolPort
MolPort-003-850-195
https://www.molport.com/shop/molecule-link/MolPort-003-850-195
ZINC
ZINC000003964126
http://zinc15.docking.org/substances/ZINC000003964126
PubMed

PubMed

TitleDatePubMed
Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
2009-02
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.
2009
[Summary and perspectives. Rivaroxaban].
2008-12
[Rivaroxaban (Xarelto): efficacy and safety].
2008-12
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
2008-12
[Rivaroxaban: clinical pharmacology].
2008-12
[Rivaroxaban: a decisive step forward in the management of postoperative thromboembolic disease?].
2008-12
[Pharmacology of heparins and direct anticoagulants].
2008-12
Rivaroxaban for thromboprophylaxis.
2008-11-13
Rivaroxaban for thromboprophylaxis.
2008-11-13
Rivaroxaban for thromboprophylaxis.
2008-11-13
Rivaroxaban for thromboprophylaxis.
2008-11-13
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
2008-11-11
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].
2008-11
[Anaesthesia and thromboembolic disease].
2008-11
[Thromboembolic disease in orthopedic surgery].
2008-11
[Rivaroxaban. The first factor Xa inhibitor].
2008-11
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty.
2008-10-22
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty.
2008-10-22
Preventing venous thromboembolism through risk assessment approaches.
2008-10-02
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
2008-10
[Always more amputations in Germany?].
2008-10
More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.
2008-10
Rivaroxaban: future in anticoagulation practice?
2008-10
[Prophylaxis of venous thromboembolism].
2008-10
[Anticoagulation in atrial fibrillation].
2008-10
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
2008-10
Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events.
2008-10
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
2008-10
Polyphosphate as a general procoagulant agent.
2008-10
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
2008-09-15
Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
2008-09-01
New developments in anticoagulation for atrial fibrillation.
2008-09
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
2008-09
Rivaroxaban: an oral direct inhibitor of factor Xa.
2008-08-15
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
2008-08
Selective factor Xa inhibition for thromboprophylaxis.
2008-07-05
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
2008-07-05
New anticoagulants--the path from discovery to clinical practice.
2008-06-26
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
2008-06-26
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
2008-06-26
Gateways to clinical trials.
2008-06
[Hematology 2008].
2008-06
Rivaroxaban, an oral direct factor Xa inhibitor.
2008-06
Gateways to clinical trials.
2008-04
New issues in oral anticoagulants.
2008
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.
2008
Brave new world: the current and future use of novel anticoagulants.
2008
The top 4 advances in antithrombotic care in the last year.
2008
Pharmacological strategies for inhibition of thrombin activity.
2008
Patents

Patents

07351823
1
08101601
1
08106192
1
08334284
1
08362015
2
08648189
1
20030153610
1
20040242660
1
JP2006513227A
1
JP2007517816A
1
JP2010505534A
1
JP2010539945A
2
JP2011502514A
9
JP2011502515A
9
JP2011510067A
60
JP2011526266A
1
JP4667044B2
1
JP5311742B2
1
JP5352461B2
1

Sample Use Guides

In Vivo Use Guide
15 mg and 20 mg tablets with food; take 10 mg tablets with or without food. For patients with CrCl >50 mL/min 20 mg orally, once daily and for patients with CrCl 15 - 50 mL/min 15 mg orally, once daily with the evening meal.
Route of Administration: Oral
In Vitro Use Guide
To evaluate the influence of prothrombin complex concentrate (PCC) on the anticoagulant effects of rivaroxaban as measured by prothrombin time (PT) and thrombin generation tests plasma and whole blood samples from healthy volunteers were spiked with Rivaroxaban (up to 800 ug/L) and prothrombin complex concentrate (PCC) was added to these samples in concentration ranges as used clinically to reverse the effects of vitamin K antagonists. Prothrombin complex concentrate does not neutralize the lengthening effect on PT and TGT lag time/T-Lag of rivaroxaban anticoagulated blood in vitro; however, total thrombin potential could be normalized.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:11:43 GMT 2025
Edited
by admin
on Mon Mar 31 18:11:43 GMT 2025
Record UNII
9NDF7JZ4M3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Rivaroxaban
DASH   EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
XARELTO
Preferred Name English
Rivaroxaban [WHO-DD]
Common Name English
Rivaroxaban [EMA EPAR]
Common Name English
JNJ-39039039
Code English
Rivaroxaban [ORANGE BOOK]
Common Name English
Rivaroxaban [MI]
Common Name English
Rivaroxaban [USP-RS]
Common Name English
(S)-Rivaroxaban
Common Name English
Rivaroxaban [INN]
Common Name English
Rivaroxaban [MART.]
Common Name English
2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-
Systematic Name English
Rivaroxaban [VANDF]
Common Name English
5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide
Systematic Name English
JNJ39039039
Code English
Rivaroxaban [JAN]
Common Name English
BAY59-7939
Code English
Rivaroxaban [USAN]
Common Name English
Rivaroxaban [EP MONOGRAPH]
Common Name English
5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide
Systematic Name English
BAY-59-7939
Code English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS XARELTO (AUTHORIZED: ARTHROPLASTY, REPLACEMENT)
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
NCI_THESAURUS C263
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
WHO-ATC B01AF01
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
NDF-RT N0000175637
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
EMA ASSESSMENT REPORTS XARELTO (AUTHORIZED: VENOUS THROMBOEMBOLISM)
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
WHO-ATC B01AX06
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
WHO-VATC QB01AF01
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
LIVERTOX NBK548015
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
LOINC 74871-5
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID3057723
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
NCI_THESAURUS
C77995
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
DRUG BANK
DB06228
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
MERCK INDEX
m9638
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY Merck Index
DAILYMED
9NDF7JZ4M3
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
WIKIPEDIA
RIVAROXABAN
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
FDA UNII
9NDF7JZ4M3
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
INN
8428
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
IUPHAR
6388
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
USAN
SS-99
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL198362
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
RXCUI
1114195
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY RxNorm
CAS
366789-02-8
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
DRUG CENTRAL
4182
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
MESH
C503223
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
PUBCHEM
9875401
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
SMS_ID
100000092811
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
LACTMED
Rivaroxaban
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
RS_ITEM_NUM
1604530
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
HSDB
8149
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
EVMPD
SUB29263
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
CHEBI
68579
Created by admin on Mon Mar 31 18:11:43 GMT 2025 , Edited by admin on Mon Mar 31 18:11:43 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of Rivaroxaban, (±)-
RACEMATE -> ENANTIOMER
COAGULATION FACTOR X HUMAN
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
COAGULATION FACTOR X HUMAN
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
Ki
CYTOCHROME P450 2J2
METABOLIC ENZYME -> SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
FACTOR XA
TARGET -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Related Record Type Details
Structure of 2-HYDROXY-3-OXO-RIVAROXABAN
METABOLITE -> PARENT
MINOR
FECAL; URINE
Structure of N-((5-CHLORO-2-THIENYL)CARBONYL)GLYCINE
METABOLITE -> PARENT
IN-VITRO
FECAL; URINE
Structure of 5-CHLORO-N-(((5S)-3-(4-((2-HYDROXYETHYL)AMINO)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-2-THIOPHENECARBOXAMIDE
METABOLITE -> PARENT
MINOR
FECAL; URINE
Structure of 2-HYDROXY-5-OXO-RIVAROXABAN
METABOLITE -> PARENT
Structure of RIVAROXABAN DIOL
METABOLITE -> PARENT
excreta 2.5% radio acitivty
Structure of 2-((4-((5S)-5-((((5-CHLORO-2-THIENYL)CARBONYL)AMINO)METHYL)-2-OXO-3-OXAZOLIDINYL)PHENYL)(2-HYDROXYETHYL)AMINO)-2-OXO-ACETIC ACID
METABOLITE -> PARENT
IN-VIVO
FECAL; URINE
Structure of 2-HYDROXY-3-OXO-RIVAROXABAN
METABOLITE -> PARENT
Related Record Type Details
Structure of N,N'-Bis(des(5-chloro-2-carvoxythienyl) rivaroxaban) urea
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-Chlororivaroxaban
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-(((5S)-2-Oxo-3-(4-(3-oxo-4-morpholinyl)phenyl)-5-oxazolidinyl)methyl)acetamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Rivaroxaban pseudodimer
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-[[(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-MORPHOLINONE, 4-(4-(5-(((1,1-DIMETHYL-3-OXOBUTYL)AMINO)METHYL)-2-OXO-3-OXAZOLIDINYL)PHENYL), (S)-
IMPURITY -> PARENT
Structure of 5-CHLORO-2-THIOPHENECARBOXYLIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Acetyl chloride
IMPURITY -> PARENT
Structure of 2-THIOPHENECARBOXAMIDE, 5-CHLORO-N-(1,1-DIMETHYL-3-OXOBUTYL)-N-((2-OXO-3-(4-(3-OXO-4-MORPHOLINYL)PHENYL)-5-OXAZOLIDINYL)METHYL), (S)-
IMPURITY -> PARENT
Structure of N-[(2S)-3-[[(5-Chloro-2-thienyl)carbonyl]amino]-2-hydroxypropyl]-N-[4-(3-oxo-4-morpholinyl)phenyl]carbamic acid
IMPURITY -> PARENT
Structure of Rivaroxaban, (R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Rivaroxaban N-hydrolyse N-5-chlorothiophene-2-carbaldehyde
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of Rivaroxaban
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966